BioSpace News Archive

Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced a supply agreement with the government of Peru for 20 million doses of Moderna’s COVID-19 vaccine to begin delivery in the first quarter of 2022.

Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced the closing of a public offering of 27,568,072 shares of its common stock.

The COVID-19 pandemic continues to create stress and anxiety for many Canadians, particularly those who do not have ready access to their regular support networks.

Gritstone bio, Inc., announced that the Compensation Committee of the company’s Board of Directors has granted six employees nonqualified stock options to purchase an aggregate of 41,800 shares of its common stock with an exercise price of $11.58, which is equal to the closing price of Gritstone’s common stock on September 14, 2021, the grant date of the awards.

Verastem Oncology, a biopharmaceutical company committed to advancing new medicines for patients with cancer, announced the grant of options to purchase 450,000 shares of its common stock and the grant of 150,000 restricted stock units to Louis J. Denis, MD, in connection with his appointment to Chief Medical Officer.

Eli Lilly and Company is voluntarily recalling lot D239382D, Expiration April 2022, of Glucagon Emergency Kit for Low Blood Sugar, to the consumer/user level.

Jasper Therapeutics, Inc. today announced the completion of its business combination with Amplitude Healthcare Acquisition Corporation

Mirati Therapeutics, Inc. today announced that in connection with the hiring, announced on September 20, 2021, of David Meek as Chief Executive Officer, Mr. Meek received an inducement award to purchase up to 150,300 shares of common stock.

Pfizer Inc. (NYSE: PFE) and OPKO Health Inc. (NASDAQ: OPK) announced today that the U.S. Food and Drug Administration (FDA) has extended the review period for the Biologics License Application (BLA) for somatrogon

TMR Research has rich experience in developing state-of-the-art reports for a wide array of markets and sectors.